Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Mi | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 246 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
Mi | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 5 | Investing.com Deutsch | ||
Mi | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Mi | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 78 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
Fr | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha | ||
Fr | Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement | 105 | GlobeNewswire (Europe) | FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment... ► Artikel lesen | |
14.05. | EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models | 2 | Benzinga.com | ||
13.05. | Channel Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | Channel Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
01.05. | Channel Therapeutics Corporation: Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules | 1 | GlobeNewswire (USA) | ||
17.04. | Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi | 1 | FiercePharma | ||
17.04. | Ligand unit Pelthos to merge with Channel Therapeutics | 1 | Seeking Alpha | ||
17.04. | Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub | 398 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries... ► Artikel lesen | |
17.04. | Channel Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
17.04. | Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | 261 | GlobeNewswire (Europe) | Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug... ► Artikel lesen | |
27.03. | Channel Therapeutics Corp - 10-K, Annual Report | 2 | SEC Filings | ||
03.03. | Channel Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
20.12.24 | Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine | 184 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen | |
18.12.24 | Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model | 195 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,474 | +1,69 % | Evotec, Lanxess, Northern Data, Redcare Pharmacy, Renk Group, Vonovia - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
VALNEVA | 2,434 | +0,83 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
MAINZ BIOMED | 1,430 | 0,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
CG ONCOLOGY | 26,680 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 20,640 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,010 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
RELAY THERAPEUTICS | 3,600 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
APOGEE THERAPEUTICS | 44,370 | 0,00 % | Guggenheim reiterates Buy on Apogee Therapeutics stock ahead of key data | ||
QIAGEN | 41,175 | +1,07 % | Kurs von Qiagen NV steigt etwas (41,29 €) | Am Aktienmarkt notiert der Anteilsschein von Qiagen NV derzeit ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 41,29 Euro. Heute hat sich im Wertpapierhandel die Qiagen NV-Aktie zwischenzeitlich... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,530 | 0,00 % | Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion | ||
ARRIVENT BIOPHARMA | 21,100 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
VERVE THERAPEUTICS | 11,215 | 0,00 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
ARCELLX | 66,28 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ALUMIS | 3,280 | 0,00 % | Alumis Inc.: Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis | SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 27,460 | 0,00 % | Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth |